Journal: iScience
Article Title: Combined prostate cancer vaccine plus immune checkpoint inhibition synergizes to eliminate prostate cancer
doi: 10.1016/j.isci.2025.114552
Figure Lengend Snippet: Preclinical evaluation of the toxic profile of the Ad-PS2 vaccine combined with αCTLA4 therapy (A) Scatterplot of the counted inflammatory cells in the liver (3 different fields at 40x) between age-matched naive mice and vaccine-treated groups of mice ( n = 3) based on histopathology studies, and (B) liver panel analytes measured in serum among the naive ( n = 3), Ad-LacZ control ( n = 5), Ad-PS2 vaccine ( n = 7), and Ad-PS2 + αCTLA4 ( n = 3) groups of mice. Data are shown as mean ± SEM with a significant difference (∗ p < 0.05) and ns = non-significant following a nonparametric Kruskal-Wallis test.
Article Snippet: Anti-mouse immune checkpoint inhibitor (ICI) antibodies for αCTLA4 (Cat. #BP0164; Clone #9D9) and αPD1 (Cat. #BP0146; Clone # RMP1-14) were purchased from BioXcell (Lebanon, NH, USA).
Techniques: Histopathology, Control